Using AI Software to Support Clinical Decisions in Cancer Treatment


The goal of providing precision techniques to cancer care is becoming increasingly complicated. According to a recent article in Inside Precision Medicine, the cause may be attributed to the corresponding increase in the number of genes needed for informed treatment decisions.

It is estimated that a medical oncologist must become familiar with approximately 3,000 pages of updated guideline information every year. In addition, case reviews and research are extremely time-consuming.

Even if there are no approved treatments for a specific disease, the oncologist may refer to actionable information plus the creation of new information and perhaps relevant clinical trials.

Details analyzing data from the xDECIDE engine and XCELSIOR PAN-CANCER registry were released last week and published in the journal AI in Precision Oncology. The team included researchers from Saint John’s Institute, Stanford University, the Rare Cancer Foundation, and xCures. xDECIDE allows providers to add new patients, review cases, and save time while considering treatment options.

By leveraging the core technology of xCures, xDECIDE saves time for oncologists and staff members. When a patient arrives at the doctor’s office both the patient and the provider can be assured of having a mutual understanding of the updated case history. Both the physician and patient will also feel reassured that expert research is being presented at the visit and every possible option has been considered.

The Treatment Options Report

The comprehensive treatment options report includes treatment options for consideration backed by information regarding access to therapy and medical rationales. The treatments with the most potential are presented to the patient. Human expertise is used throughout the entire procedure.

The treatment options report provides treatments for consideration, with supporting medical rationales and information regarding access to therapy. There is no cost for the options report to either the patient or the provider.

Linked providers and patients receive xCure reports adding additional data for discussion and review.



Rose Duesterwald

Rose Duesterwald

Rose became acquainted with Patient Worthy after her husband was diagnosed with Acute Myeloid Leukemia (AML) six years ago. During this period of partial remission, Rose researched investigational drugs to be prepared in the event of a relapse. Her husband died February 12, 2021 with a rare and unexplained occurrence of liver cancer possibly unrelated to AML.

Share this post